Pharmanet claims success with burns trials

Leederville-based Pharmanet Group Ltd has announced positive results from research into its protein fragment drug which inhibits the reaction to UVB burns.

Below is the announcement - the original had pictures of the drug's results:

PROTEIN FRAGMENT DRUG SHOWS POTENT ANTI-INFLAMMATORY EFFECTS IN BURNS ============================================
Pharmanet Group Ltd (ASX: PNO) announced today that its proprietary protein fragment drug candidate CS-104 has been shown to be effective in limiting post-traumatic inflammatory processes following acute burns.
The research into the effect of CS-104 in the suppression of inflammation resulting from UVB burns in humans, can be seen in the images below.
When applied as a topical cream, CS-104 has been shown to suppress the normal biological response to UVB burning most significantly when applied within 5 minutes of the injury.
When applied 4 hours after injury CS-104 still provides a significant suppressive effect.
The work has been carried out by Pharmanet's drug discovery subsidiary Cambridge Scientific Pty Ltd (Cambridge) which has been working on acute injury cascade mediators for almost 2 years.
CS-104, which is part of CS-100 drug development platform, is held by Cambridge following the sale and licensing of the MPL-TL100 platform to Molecular Pharmacology (USA) Limited.
CS-104 is of a size and structure which allows it to rapidly target key biological processes earlier in the injury cascade than current therapeutic approaches.
The study has shown that CS-104 is most effective when applied shortly after injury, and is expected to lead to significant reductions in scaring.
Research continues in this field.
Pharmanet's drug discovery program was recently expanded to include additional in vitro programs which are to be undertaken by independent scientists at Government supported medical research facilities in Perth, Western Australia, The new laboratory currently under development at the company's premises is expected to allow the company to accelerate its current development program with more cost and time effective research and developments during 2006.